Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Cue Biopharma ( (CUE) ) is now available.
On November 17, 2025, Cue Biopharma, Inc. announced the termination of employment for its Chief Medical Officer, Dr. Matteo Levisetti, effective November 28, 2025. Dr. Levisetti will receive severance benefits, including a lump sum cash payment and continued health insurance coverage under COBRA, as part of his separation agreement.
The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
Cue Biopharma’s overall stock score is heavily impacted by its poor financial performance and valuation challenges. The technical analysis suggests potential for a rebound, but current momentum is negative. Strategic improvements are necessary for future stability.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Average Trading Volume: 264,266
Technical Sentiment Signal: Sell
Current Market Cap: $45.68M
See more data about CUE stock on TipRanks’ Stock Analysis page.